Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 16/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465789 | 0.92 | ABCG2 (0.72) | ABCG2ABCB1ALDH1A1LMNATP53 | |
| SCHEMBL3712664 | 0.84 | ABCG2 (1.00) | ABCG2ABCB1LMNATP53 | |
| SCHEMBL23438776 | 0.80 | PKM (0.53) | ABCG2ABCB1ALDH1A1PKMLMNA | |
| SCHEMBL18689299 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1 | |
| SCHEMBL4264083 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1LMNA | |
| SCHEMBL13912132 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1LMNATP53 | |
| SCHEMBL1491468 | 0.79 | ABCG2 (0.50) | ABCG2ABCB1PKMLMNATP53 | |
| SCHEMBL13912108 | 0.77 | ABCG2 (0.92) | ABCG2ABCB1ALDH1A1LMNA | |
| SCHEMBL13912101 | 0.77 | ABCG2 (0.92) | ABCG2ABCB1LMNATP53 | |
| SCHEMBL13912103 | 0.77 | ABCG2 (0.92) | ABCG2ABCB1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | AKR1C4, AKR1C2, AKR1C3 | ABCG2 833/4885ABCB1 1727/4885ALDH1A1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.